Meros Equity
Personal Account
Kymera Therapeutics
IPO KYMR.NASDAQ Past

Kymera Therapeutics

Biotechnology company that specializes in the field of targeted protein degradation

Ticker

KYMR.NASDAQ

Market

us

Foundation year

2017

Potential

160.55%

Close date

8/27/2020

IPO date

8/20/2020

Placement price

$20

Profitability

60.55%

About

Total Funding

$454M

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.

Number of employees

100 - 250

Headquarters

Cambridge, Massachusetts, United States

Meros Equity

2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.